Epidemiology and treatment approaches in management of invasive fungal infections

Clinical Epidemiology

Volumn 3, Issue 1, 2011, Pages 175-191

  Kriengkauykiat, Jane ^a   Ito, James I ^a   Dadwal, Sanjeet S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Antifungal agents; Immunosuppression; Invasive fungal infections

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; DEFERASIROX; DEFERIPRONE; ECHINOCANDIN; FG 3409; FLUCONAZOLE; FLUCYTOSINE; FUNGUS VACCINE; INTERLEUKIN 10; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA PARAPSILOSIS; CANDIDEMIA; CANDIDIASIS; CELLULAR IMMUNITY; CLINICAL FEATURE; CRYPTOCOCCOSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FUNGUS CULTURE; GENETIC PREDISPOSITION; HIGH RISK POPULATION; HISTOPATHOLOGY; HOST RESISTANCE; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; NEPHROTOXICITY; NONHUMAN; SYSTEMIC MYCOSIS; UNSPECIFIED SIDE EFFECT; ZYGOMYCOSIS;

EID: 79958072618     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S12502     Document Type: Article

References (151)

1. Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patientsf with invasive aspergillosis. Clin Infect Dis. 2010; 50(12):1559-1567.
2. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091-1100.
3. Park BJ, Pappas PG, Marr KA, et al. Recent epidemiology of zygomycosis among organ transplant and stem cell transplant recipients: Results from the TRANSNET surveillance network. Abstract M-618 presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007.
4. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010; 50(8):1101-1111.
5. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis. 1995; 171(6): 1545-1552.
6. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-1238.
7. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(7):909-917.
8. Brayman KL, Stephanian E, Matas AJ, et al. Analysis of infectious complications occurring after solid-organ transplantation. Arch Surg. 1992;127(1):38-47.
9. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis. 1993;16(5):677-688.
10. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs fluconazole or intraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-359.
11. Mattiuzzi GN, Kantarjian H, Faderl S, et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004;100(3):581-589.
12. Vreugdenhil G, Van Dijke BJ, Donnelly JP, et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma. 1993;11(5-6): 353-358.
13. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis. 1999; 28(2):250-255.
14. Lehrnbecher T, Frank C, Engels K, Kriener S, Groll AH, Schwabe D. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 2010;61(3):259-265.
15. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-2329.
16. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-415.
17. Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: A multicenter retrospective analysis of 83 cases. Clin Infect Dis. 2004;39(2):192-198.
18. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol. 2010;48(7):2373-2380.
19. Vazquez JA. Invasive fungal infections in the intensive care unit. Semin Respir Crit Care Med. 2010;31(1):79-86.
20. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care. 2010;16(5):445-452.
21. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48(12):1695-1703.
22. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: Antimicrobial- resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29(11): 996-1011.
23. Neumann PR, Rakower SR. The risk of positive cultures for Candida in the critically ill patient. Crit Care Med. 1978;6(2):73-76.
24. Kett DH, Azoulay E, Echeverria PM, Vincent JL. Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in a intensive care unit study. Crit Care Med. December 16, 2010. [Epub ahead of print].
25. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265-273.
26. Ambrosioni J, Bouchuiguir-Wafa K, Garbino J. Emerging invasive zygomycosis in a tertiary care center: Epidemiology and associated risk factors. Int J Infect Dis. 2010;14 Suppl 3:e100-e103.
27. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007;40(5):451-456.
28. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39(7):425-429.
29. Suzuki K, Sugawara Y, Sekine T, Nakase K, Katayama N. Breakthrough disseminated zygomycosis induced massive gastrointestinal bleeding in a patient with acute myeloid leukemia receiving micafungin. J Infect Chemother. 2009;15(1):42-45.
30. Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: Yeasts and filamentous fungi. Rev Iberoam Micol. 2008;25(2):101-106. Spanish.
31. Chapeland-Leclerc F, Hennequin C, Papon N, et al. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother. 2010;54(3):1360-1362.
32. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MG, Denning DW. High prevalence of antifungal resistance in Candida spp. from patients with acquired immunodeficiency syndrome. J Antimicrob Chemother. 1994;34(5):659-668.
33. Westbrook SD, Wiederhold NP, Vallor AC, et al. Loss of in vitro resistance in Candida glabrata following discontinuation of fluconazole prophylaxis in a hematopoietic stem cell transplantation patient. Med Mycol. 2010;48(3):557-560.
34. Laverdière M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother. 2006;57(4):705-708.
35. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51(6):1897-1904.
36. Rajendran R, Mowat E, McCulloch E, et al. Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity. Antimicrob Agents Chemother. February 14, 2011. [Epub ahead of print].
37. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009;15(7):1068-1076.
38. Schelenz S, Abdallah S, Gray G, et al. Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors. J Oral Pathol Med. 2011;40(1):83-89.
39. Storek J, Dawson MA, Lim LC, et al. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation. Bone Marrow Transplant. 2004;33(3):337-346.
40. Fishman JA, Issa NC. Infection in organ transplantation: Risk factors and evolving patterns of infection. Infect Dis Clin North Am. 2010; 24(2):273-283.
41. Egerer G, Geist MJ. Posaconazole prophylaxis in patients with acute myelogenous leukaemia - results from an observational study. Mycoses. 2011;54 Suppl 1:7-11.
42. Orasch C, Weisser M, Mertz D, et al. Comparison of infectious complications during induction/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45(3):521-526.
43. Bodey GP. Infectious complications of acute leukemia. Med Times. 1966;94(9):1076-1085.
44. Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66 Suppl 1:5-14.
45. Portugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol. 2009;27(23):3849-3854.
46. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175(6):1459-1466.
47. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 1997;19(8):801-808.
48. Van Burik JA, Carter SL, Freifeld AG, et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T celldepleted unrelated bone marrow: Analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(12):1487-1498.
49. De La Rosa GR, Champlin RE, Kontoyiannis DP. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transpl Infect Dis. 2002; 4(1):3-9.
50. Schmeiser T, Wiesneth M, Bunjes D, et al. Infectious complications after allogeneic bone marrow transplantation with and without T-cell depletion of donor marrow. Infection. 1989;17(3):124-130.
51. Pirsch JD, Maki DG. Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Increased susceptibility to fungal infections. Ann Intern Med. 1986; 104(5):619-631.
52. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34(2):115-121.
53. Labbe AC, Su SH, Laverdiere M, et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant. 2007;13(10):1192-1200.
54. Alderson JW, Van Dinter TG Jr, Opatowsky MJ, Burton EC. Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: A case study and review of the literature. Med Gen Med. 2005;7(3):7.
55. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. 2008;359(17):1766-1777.
56. Sainz J, Salas-Alvarado I, Lopez-Fernandez E, et al. TNFR1 mRNA expression level and TNFR1 gene polymorphisms are predictive markers for susceptibility to develop invasive pulmonary aspergillosis. Int J Immunopathol Pharmacol. 2010;23(2):423-436.
57. Carvalho A, Cunha C, Carotti A, et al. Polymorphisms in Toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation. Exp Hematol. 2009;37(9):1022-1029.
58. Seo KW, Kim DH, Sohn SK, et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36(12):1089-1095.
59. Panackal AA, Li H, Kontoyiannis DP, et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis. 2010;50(12):1588-1597.
60. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001;33(2):177-186.
61. Segal BH. Aspergillosis. N Engl J Med. 2009;360(18):1870-1884.
62. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis. 1992;11(2):99-109.
63. Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135(5): 715-719.
64. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28(5): 1071-1079.
65. Pagano L, Antinori A, Ammassari A, et al. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. Eur J Haematol. 1999;63(2):77-85.
66. Fine JD, Miller JA, Harrist TJ, Haynes HA. Cutaneous lesions in disseminated candidiasis mimicking ecthyma gangrenosum. Am J Med. 1981;70(5):1133-1135.
67. Kanski J, Pavesio C, Tuft S. Endophthalmitis. In: Ocular Inflammatory Disease. Philadelphia, PA: Elsevier; 2006.
68. Rabinovici R, Szewczyk D, Ovadia P, Greenspan JR, Sivalingam JJ. Candida pericarditis: Clinical profile and treatment. Ann Thorac Surg. 1997;63(4):1200-1204.
69. Pagano L, Mele L, Fianchi L, et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica. 2002;87(5): 535-541.
70. Miller DJ, Mejicano GC. Vertebral osteomyelitis due to Candida species: Case report and literature review. Clin Infect Dis. 2001;33(4): 523-530.
71. Singh N, Husain S. Aspergillus infections after lung transplantation: Clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003;22(3):258-266.
72. Kleinschmidt-DeMasters BK. Central nervous system aspergillosis: A 20-year retrospective series. Hum Pathol. 2002;33(1):116-124.
73. Walsh TJ, Hier DB, Caplan LR. Fungal infections of the central nervous system: comparative analysis of risk factors and clinical signs in 57 patients. Neurology. 1985;35(11):1654-1657.
74. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-1821.
75. Anaissie E, Bodey GP, Kantarjian H, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med. 1991;91(2):142-150.
76. Samuels BI, Pagani JJ, Libshitz HI. Radiographic features of candida infections. In: Bodey GP, editor. Candidiasis: Pathogenesis, Diagnosis and Treatments. New York, NY: Raven Press; 1993.
77. Semelka RC, Shoenut JP, Greenberg HM, Bow EJ. Detection of acute and treated lesions of hepatosplenic candidiasis: Comparison of dynamic contrast-enhanced CT and MR imaging. J Magn Reson Imaging. 1992;2(3):341-345.
78. Semelka RC, Kelekis NL, Sallah S, Worawattanakul S, Ascher SM. Hepatosplenic fungal disease: Diagnostic accuracy and spectrum of appearances on MR imaging. AJR Am J Roentgenol. 1997;169(5): 1311-1316.
79. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1 $ 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41(5):654-659.
80. Logan PM, Primack SL, Miller RR, Muller NL. Invasive aspergillosis of the airways: Radiographic, CT, and pathologic findings. Radiology. 1994;193(2):383-388.
81. Kuhlman JE, Fishman EK, Siegelman SS. Invasive pulmonary aspergillosis in acute leukemia: Characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis. Radiology. 1985;157(3): 611-614.
82. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: Implications for diagnosis and management. Clin Infect Dis. 2002;35(8):909-920.
83. Krcmery V Jr, Kunova E, Jesenska Z, et al. Invasive mold infections in cancer patients: 5 years' experience with Aspergillus, Mucor, Fusarium and Acremonium infections. Support Care Cancer. 1996;4(1):39-45.
84. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40(12):1762-1769.
85. Wheat LJ. Approach to the diagnosis of invasive aspergillosis and candidiasis. Clin Chest Med. 2009;30(2):367-377, viii.
86. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis. 1998;27(3):603-618.
87. Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol. 2009;47(6):1942-1946.
88. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. Eurofung Network. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Infect Dis. 2003;51(1):45-52.
89. Baddley JW, Marr KA, Andes DR, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant- Associated Infection Surveillance Network. J Clin Microbiol. 2009; 47(10):3271-3275.
90. Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother. 1999;43(1):169-170.
91. Diekema D, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voricaonzole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003;41(8):3623-3626.
92. Dodds Ashley ES, Lewis R, Lewis JS, Marin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006; 43 Suppl:S28-S39.
93. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005;35(5):509-513.
94. Summers KK, Hardin TC, Gore SJ, Graybill JR. Therapeutic drug monitoring of systemic antifungal therapy. J Antimicrob Chemother. 1997;40(6):753-764.
95. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201-211.
96. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020-2029.
97. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45(7):883-893.
98. Moore CB, Denning DW. Tolerance and fungicidality in vitro of caspofungin, micafungin and anidulafungin against Candida guilliermondii. Abstract M-230 presented at the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA.
99. Thompson GR 3rd, Cadena J, Patterson TF. Overview of antifungal agents. Clin Chest Med. 2009;30(2):203-215, v.
100. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):27-60.
101. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis. 2007;44(1):2-12.
102. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53(5):337-349.
103. Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer. 2006;106(2):466-473.
104. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563-1571.
105. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503-535.
106. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503-509.
107. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother. 1998;42(11):3018-3021.
108. Lass-Florl C, Mayr A, Perkhofer S, et al. Activities of antifungal agents against yeasts and filamentous fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2008;52(10):3637-3641.
109. Van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis. 2006;42(7):e61-e65.
110. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003;36(10):1221-1228.
111. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004; 39(6):797-802.
112. Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: A randomized pilot study (Combistrat trial). Cancer. 2007;110(12):2740-2746.
113. Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G, et al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 2005;49(3):1232-1235.
114. Schaffner A, Annette B. Amphotericin B refractory aspergillosis after itraconazole: Evidence for significant antagonism. Mycoses. 1993;36(11-12):421-424.
115. Popp AI, White MH, Quadri T, Walshe L, Armstrong D. Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study. Int J Infect Dis. 1999;3(3):157-160.
116. Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin Microbiol Infect. 2004;10(10):925-928.
117. O'Shaughnessy EM, Meletiadis J, Stergiopoulou T, Demchok JP, Walsh TJ. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother. 2006;58(6):1168-1176.
118. Meletiadis J, Stergiopoulou T, O'Shaughnessy EM, Peter J, Walsh TJ. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: Analysis by a new response surface model. Antimicrob Agents Chemother. 2007;51(6):2053-2064.
119. Ibrahim AS, Edwards JE, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother. 2006;58(5):1070-1073.
120. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J, Ibrahim AS. Recent advances in the management of mucormycosis: From bench to bedside. Clin Infect Dis. 2009;48(12):1743-1751.
121. Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993;91(5):1979-1986.
122. Kasapoglu F, Coskun H, Ozmen OA, Akalin H, Ener B. Acute invasive fungal rhinosinusitis: Evaluation of 26 patients treated with endonasal or open surgical procedures. Otolaryngol Head Neck Surg. 2010;143(5):614-620.
123. Tumbarello M, Posteraro B, Trecarichi EM, et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol. 2007;45(6):1843-1850.
124. Nucci M, Anaissie E, Betts RF, et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: Analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis. 2010;51(3):295-303.
125. Ito JI, Kriengkauykiat J, Dadwal SS, Arfons LM, Lazarus HM. Approaches to the early treatment of invasive fungal infection. Leuk Lymphoma. 2010;51(9):1623-1631.
126. Michallet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol. 2009;27(20):3398-3409.
127. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93.
128. Maertens J, Theunissen K, Lodewyck T, Lagrou K, Van Eldere J. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses. 2007; 50 Suppl 1:2-17.
129. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;357(4):335-347.
130. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527-1533.
131. Van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407-1416.
132. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis- related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96(6):2055-2061.
133. Peel M, Mamai A, Fan W, et al. New beta-1,3-glucan synthase (GS) inhibitors with potent antifungal activity. Abstract presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.
134. Perkhofer S, Lechner V, Lass-Florl C. In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2009;53(4): 1645-1647.
135. Watanabe N, Horii T, Miyazaki M, Hata K. E1210, a new broadspectrum antifungal, inhibits glycosylphosphatidylinositol (GPI) biosynthesis and effects Candida albicans cell characteristics. Abstract F1-841 presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.
136. Miyazaki M, Horii T, Hata K, Watanabe N. In vitro antifungal activity of E1210: A novel antifungal with activity against clinically important yeasts and moulds. Abstract F1-840 presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.
137. Warn PA, Sharp A, Gould J, et al. Efficacy of FG3409 a new antifungal agent, in reducing tissue burden in murine models of disseminated aspergillosis. Abstract F1-1182 presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 25-28, 2008.
138. Law D, Fothergrill AW, Chen SC, Sorrell TC, Birch M. The activity of FG3622 and FG3409 against Scedosporium spp. Abstract F1-858 presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.
139. Krysan D, Baxter BK, Didone L. Phosphoinositide-dependent kinase 1 (PDK1) inhibitors are a novel class of cell wall-targeted antifungal small molecules. Abstract F1-859 presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.
140. Nguyen D, Li J, Akache B, et al. MGCD290: A novel small molecule, modulates azole antifungal activity through specific inhibition of the histone deacetylase HOS2. Abstract M-1919 presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.
141. Krishnan-Natesan S, Swaminathan S, Chandrasekar P. Extended spectrum triazole plus type II topoisomerase inhibitor (TI) against azole-resistant (R) isolates of Aspergillus: Synergistic interaction in vitro. Abstract M-396 presented at 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.
142. McKee J, Rabinow B, Cook C, Gass J. Nanosuspension formulation of itraconazole eliminates the negative inotropic effect of Sporanox in dogs. J Med Toxicol. 2010;6(3):331-336.
143. Segal BH, Kwon-Chung J, Walsh TJ, et al. Immunotherapy for fungal infections. Clin Infect Dis. 2006;42(4):507-515.
144. Romani L. Cell mediated immunity to fungi: A reassessment. Med Mycol. 2008;46(6):515-519.
145. Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup VP, Romani L. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol. 2000;165(1):381-388.
146. Beck O, Koehl U, Tramsen L, et al. Enumeration of functionally active anti-Aspergillus T-cells in human peripheral blood. J Immunol Methods. 2008;335(1-2):41-45.
147. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106(13):4397-4406.
148. Ito JI, Lyons JM. Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J Infect Dis. 2002; 186(6):869-871.
149. Bozza S, Gaziano R, Lipford GB, et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect. 2002;4(13):1281-1290.
150. Bozza S, Montagnoli C, Gaziano R, et al. Dendritic cell-based vaccination against opportunistic fungi. Vaccine. 2004;22(7):857-864.
151. Cassone A. Fungal vaccines: Real progress from real challenges. Lancet Infect Dis. 2008;8(2):114-124.